Exicure, Inc. (NASDAQ: XCUR) today announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value. After a strategic review of the Company’s business plans and objectives and its existing cash resources, the Company’s Board of Directors has approved the following:

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development, and neuroscience. For further information, see www.exicuretx.com.

https://exicuretx.com/

Chicago

Exicure

Exicure, Inc. Enters Into Definitive Agreement With Cbi Usa, Inc. For $5.4 Million Equity Financing And Announces Implementation Of Strategic Measure To Reduce Cash Burn And Prioritize Strategic Alternatives

Exicure, Inc. Enters Into Definitive Agreement With Cbi Usa, Inc. For $5.4 Million Equity Financing And Announces Implementation Of Strategic Measure To Reduce Cash Burn And Prioritize Strategic Alternatives

Description

Company Information

Related People

Exicure, Inc. Enters Into Definitive Agreement With Cbi Usa, Inc. For $5.4 Million Equity Financing And Announces Implementation Of Strategic Measure To Reduce Cash Burn And Prioritize Strategic Alternatives

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information